AusperBio Secures $63 Million Series B2 Financing to Propel AHB‑137 Development

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively “AusperBio”) announced that it has closed a USD 63 million Series B2 financing round. The round was co‑led by Qiming Venture Partners and a globally‑renowned industrial‑investment firm, with participation from top domestic investors such as Hankang Capital, CDH VGC, Yuanbio Ventures, Sherpa Healthcare Partners, and Genesis Capital. This marks AusperBio’s second successful raise in 2025, bringing the company’s total capital inflow for the year to over USD 113 million.

Funding Highlights

Strategic Uses of Capital

1. Accelerate Clinical Development of AHB‑137 – The lead small‑molecule candidate targeting the Hsp90‑Cdc37 complex is slated for a pivotal Phase II trial in early‑stage solid tumours.
2. Support Future Commercialization & Industrialization – Funding will underpin pre‑commercial manufacturing scale‑up, regulatory filing preparations, and early‑stage market access strategies.
3. Expand Innovation Pipeline – Capital will back the discovery of next‑generation protein‑degradation and targeted‑oncology assets.
4. Strengthen Global Talent Pool – AusperBio plans to recruit senior scientists, clinical experts, and regulatory specialists in China and the U.S.

Market Perspective

• Investor Confidence: The robust investor mix signals strong confidence in AusperBio’s technology platform and its ability to deliver on clinical milestones.
• Competitive Edge: AHB‑137’s mechanism of action offers a differentiated approach to overcoming resistance in HER2‑positive and KRAS‑mutated cancers, positioning AusperBio ahead of several peers in the protein‑degradation space.
• Future Outlook: With the Series B2 capital, AusperBio aims to reach first‑in‑class data in Q3 2026 and prepare for an FDA filing in 2027, potentially unlocking a multi‑billion‑dollar market.-Fineline Info & Tech